Shuttle Pharma Ropidoxuridine Phase 2 trial nears 50% enrollment

Shuttle Pharmaceuticals (SHPH) provided a corporate update, highlighting that its Phase 2 trial of Ropidoxuridine for glioblastoma has nearly 50% enrollment, with 84% of enrolled patients completing all seven cycles. Ropidoxuridine is reported as well tolerated. The company aims to finalize enrollment later this year, with data readout in 2026. Other updates include a sponsored research agreement with UCSF for its Diagnostics subsidiary, a provisional patent filing for a PSMA-targeted PARP inhibitor, three new board appointments, and a strengthened balance sheet with $4.5M cash at March 31. Dr. Anatoly Dritschilo resigned as CSO and board director, and Michael Vander Hoek, VP, Regulatory, announced his retirement.